RT @sitcancer: #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gast…
#JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial https://t.co/HjWLnbjr4z https://t.co/sw
RT @sitcancer: #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gast…
RT @sitcancer: #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gast…
#JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial https://t.co/HjWLnbjr4z https://t.co/ZQ
RT @sitcancer: #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gast…
RT @sitcancer: #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gast…
#JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial https://t.co/HjWLnbjr4z https://t.co/Go
RT @sitcancer: New #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced…
New #JITC Research: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial https://t.co/HjWLnbjr4z https://t.c